Washington D.C. [USA], Sep 08 (ANI): Turns out, disease-fighting T cells, elicited from vaccines, do not require glucose for their rapid reproduction, which may help the development of immunotherapy for cancer patients, a new study has revealed.
Washington D.C. [USA], August 1 (ANI): Seems like cancer tumours and proteins are not really good to each other. A new study has discovered that inhibiting a previously known protein could reduce tumor burdens and enhance the effectiveness of immunotherapy treatments.
New Delhi [India], Feb 9 (ANI-NewsVoir): One of the most recent advancements in cancer treatments is Immunotherapy with "dendritic cells". It has been proven beneficial in the case of skin, kidney, breast, pancreatic, colon, ovarian and prostate cancer. In India LDG India has initiated th
Washington D.C. [USA], Jan 9 (ANI): According to a research, melanoma patients may live longer if they take beta blockers, a class of drugs used to manage abnormal heart rhythm and prevent heart attacks.
Washington D.C. [USA], December 12 (ANI): A team of British researchers has suggested that a simple, non-invasive procedure can indicate how long a cancer patient may survive and whether they are likely to respond to immunotherapy.
Washington D.C. [USA], December 6 (ANI): Good news! A simple blood test of skin cancer patients can now help doctors to predict the chances of an aggressive cancer returning years before the symptoms appear, suggests a recent study.
Washington D.C. [USA], Nov 8 (ANI): A new category of immunotherapies, called checkpoint inhibitors, appears safe to use in patients with both advanced malignancies and HIV, according to a recent study.
New Delhi [India], July 24 (ANI): Toronto Recombinant Antibody Centre (TRAC) from the University of Toronto, Canada agreed to license MedGenome's patented cancer immunotherapy solution OncoPept to develop biomarkers for their drug candidates against immune modulators to treat cancer.
New Delhi [India], July 22 (ANI): Toronto Recombinant Antibody Centre (TRAC) from the University of Toronto, Canada agreed to license MedGenome's patented cancer immunotherapy solution OncoPept to develop biomarkers for their drug candidates against immune modulators to treat cancer.
New Delhi [India], July 22 (ANI): Toronto Recombinant Antibody Centre (TRAC) from the University of Toronto, Canada agreed to license MedGenome's patented cancer immunotherapy solution OncoPept to develop biomarkers for their drug candidates against immune modulators to treat cancer.